Macular Thickness Changes after Intracameral Injection of Vancomycin in Cataract Surgery

855 Words Feb 23rd, 2018 3 Pages
The study recruited 60 eyes of 41 patients. Eligible patients were those aged 65 to 80 with senile cataract and no other concomitant disease that would prevent a postoperative best corrected visual acuity (BCVA) of 20/40 or better. Exclusion criteria included history of ocular surgery or trauma, corneal disease, glaucoma, uveitis, vitreous opacities, retinopathy or visual pathway defects. Other exclusion criteria were current treatment with systemic steroids, immunosuppressants, anticoagulants or prostaglandin analogue eye drops. Patients with intraoperative complications or extended surgical time were also excluded.

After informed consent was obtained, participants with history of allergy to penicillin were assigned to the vancomycin group (Group 1). An equal number of patients were selected at random and assigned to the control group (Group 2). Information gathered from patients included date of birth, sex, history of drug allergy and systemic diseases, medication use and surgeon. Patients in Group 1 received an intracameral injection of vancomycin (1 mg in 0.1 ml), whereas those in Group 2 received an intracameral injection of cefuroxime (1 mg in 0.1 ml). Vancomycin injection was prepared from the commercially available vancomycin…

More about Macular Thickness Changes after Intracameral Injection of Vancomycin in Cataract Surgery